Roche Acquires Diabetes Biotech Marcadia
In the wake of its taspoglutide disappointment, Roche is acquiring privately-owned U.S. metabolic treatment maker Marcadia Biotech for an undisclosed sum.
In the wake of its taspoglutide disappointment, Roche is acquiring privately-owned U.S. metabolic treatment maker Marcadia Biotech for an undisclosed sum.